Crestor European Label Changes Prompt FDA Public Health Advisory; Safety Review Ongoing
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA is using European label update as an opportunity to remind physicians of three "key safety messages" contained in Crestor's U.S. label. FDA is not recommending changes to the U.S. label, pending an evaluation of postmarketing reports of rhabdomyolysis.
You may also be interested in...
AstraZeneca’s Crestor Label Revised With Stronger Rhabdomyolysis Warnings
Labeling now emphasizes increased risk of rhabdomyolysis, especially at 40 mg dose, but FDA reaffirms that muscle toxicity is seen across the statin class and is not unique to rosuvastatin. Labeling also recommends caution in dosing in patients of Asian descent due to increased elevation in rosuvastatin exposure.
AstraZeneca’s Crestor Label Revised With Stronger Rhabdomyolysis Warnings
Labeling now emphasizes increased risk of rhabdomyolysis, especially at 40 mg dose, but FDA reaffirms that muscle toxicity is seen across the statin class and is not unique to rosuvastatin. Labeling also recommends caution in dosing in patients of Asian descent due to increased elevation in rosuvastatin exposure.
Crestor Safety Data Under FDA Review; 11 Reports Of Rhabdomyolysis At 10 Mg Dose
The agency appears unlikely to make a significant change in the regulatory status of the statin in the near term; FDA notes that most of the reported cases of rhabdomyolysis and renal failure could be attributed to the underlying disease or concomitant medications. Public Citizen renews call for Crestor's withdrawal in Lancet article.